Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, ...
Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 ...
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...
(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
On Friday, 2Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $4.93 which represents a slight increase of $0.17 or 3.57% from the prior close of $4.76. The stock opened at $4.83 and ...
Shares of 2seventy bio (NASDAQ:TSVT) lost ~16% in the premarket Wednesday after the cancer drug developer and its partner Bristol Myers Squibb (NYSE:BMY) announced plans to discontinue enrollment ...
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback